Granahan Investment Management Trims Edgewise Therapeutics Holdings

Mutual fund reduces stake in biotech company by 16.2% in Q3

Mar. 16, 2026 at 10:38am

Got story updates? Submit your updates here. ›

Granahan Investment Management LLC reduced its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 16.2% in the third quarter, according to a recent SEC filing. The mutual fund now owns 339,617 shares of the company's stock, down from 405,478 shares previously.

Why it matters

Edgewise Therapeutics is a clinical-stage biotech company focused on developing treatments for rare diseases. Granahan Investment Management's reduced stake could signal a shift in investor sentiment or portfolio strategy, which could impact the company's stock price and future funding prospects.

The details

According to the filing, Granahan Investment Management sold 65,861 shares of Edgewise Therapeutics during the third quarter. The fund now owns about 0.32% of the company's outstanding shares, down from 0.38% previously. Edgewise Therapeutics is developing a novel inhibitor of the TRPC5 calcium channel for the treatment of kidney disorders such as focal segmental glomerulosclerosis (FSGS).

  • Granahan Investment Management reduced its Edgewise Therapeutics holdings in the third quarter of 2026.

The players

Granahan Investment Management LLC

A mutual fund that previously owned a 0.38% stake in Edgewise Therapeutics.

Edgewise Therapeutics, Inc.

A clinical-stage biotech company developing treatments for rare diseases, including a novel inhibitor of the TRPC5 calcium channel for kidney disorders.

Got photos? Submit your photos here. ›

The takeaway

Granahan Investment Management's reduced stake in Edgewise Therapeutics could signal a shift in investor sentiment around the biotech company's prospects, though the reasons behind the fund's portfolio changes are not entirely clear. Edgewise will need to continue demonstrating progress with its pipeline to maintain investor confidence and secure future funding.